ArticleCellular and molecular life sciences : CMLS2026
GFPT2 promotes macrophage dysfunction in atherosclerosis via ACADL glycosylation-dependent suppression of ACADL and Arg1.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtherosclerosis (AS) is a chronic inflammatory disease characterized by lipid-laden macrophage foam cell formation and defective efferocytosis. This study aims to investigate the impact of GFPT2 on macrophage function in AS and its underlying mechanisms.
methodsWe established an AS model using high-fat diet-fed ApoE−/− mice and ox-LDL-treated RAW264.7 and bone marrow-derived macrophages. H&E staining was conducted to examine histopathological changes in the abdominal aorta. Foam cell formation was evaluated by Oil-red-O staining and Dil-ox-LDL uptake, while efferocytosis was measured using apoptotic thymocyte clearance assays. Protein glycosylation was analyzed via PNGase F digestion and site-directed mutagenesis. GFPT2 knockdown and overexpression were performed to assess its functional role.
resultsGFPT2 was upregulated in abdominal aortic tissues and peritoneal macrophages from AS mice, as well as ox-LDL-treated macrophages. In vitro, GFPT2 knockdown reduced foam cell formation, enhanced macrophage efferocytosis, suppressed pro-inflammatory responses, and attenuated mitochondrial ROS production. Notably, GFPT2 downregulated ACADL and Arg1 expression by promoting ACADL N-glycosylation. Moreover, GFPT2 disrupted macrophage function in AS models through regulating Arg1. ACADL knockdown suppressed GFPT2 knockdown-improved macrophage function in AS models. Furthermore, GFPT2 knockdown attenuated the ox-LDL-induced activation of NF-κB and STAT2 and suppression of PPARγ expression. In vivo, GFPT2 knockdown improved serum lipid profile, ameliorated plaque burden, enhanced macrophage efferocytosis, and reduced systemic inflammation in AS mice.
conclusionOur findings revealed a novel GFPT2-ACADL-Arg1 regulatory axis in AS, where GFPT2 suppressed Arg1 expression via promoting ACADL glycosylation, thereby promoting foam cell formation, impairing efferocytosis, and exacerbating inflammation. Moreover, GFPT2 regulated key transcriptional regulators (NF‑κB, STAT2, PPARγ). These results identified GFPT2 as a pivotal regulator of macrophage homeostasis in AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.